Myeloma

Isatuximab & Carfilzomib: New Myeloma Treatment Trial

by

New Treatment Approach Significantly Improves Outcomes for Multiple Myeloma Patients Groundbreaking results from the phase 3 IsKia trial reveal a substantial improvement in treatment efficacy for individuals newly diagnosed with multiple myeloma who are eligible for stem cell transplantation. Patients receiving isatuximab in combination with carfilzomib, lenalidomide, and dexamethasone before and after transplant demonstrated significantly … Read more

Smoldering Myeloma Risk: Advanced Stratification & Prediction

by

New Algorithm Dramatically Improves Multiple Myeloma Risk Prediction A groundbreaking new algorithm promises to significantly enhance the accuracy of predicting disease progression in individuals with smoldering multiple myeloma. The tool, developed by researchers, leverages the power of longitudinal biomarker dynamics to identify those at highest risk, potentially enabling earlier intervention and improved patient outcomes. This … Read more

Multiple Myeloma: Advances in Treatment & Longer Survival

by

Multiple Myeloma: Advances in Treatment Offer Hope for Extended Lifespans Recent breakthroughs in the understanding and treatment of multiple myeloma are significantly improving patient outcomes, offering longer lives and enhanced quality of life. From innovative therapies like CAR-T cell therapy to targeted agents like belantamab mafodotin, the landscape of myeloma treatment is rapidly evolving. Understanding … Read more

Myeloma: Escaping T-Cell Therapy & GPRC5D Resistance

by

Mechanisms of Resistance Emerge in Multiple Myeloma Patients Treated with Talquetamab New research reveals how multiple myeloma, a challenging blood cancer, can develop resistance to the innovative therapy talquetamab. A comprehensive analysis of patient samples indicates that the cancer cells employ several strategies to evade the immune system’s attack, even when initially responding to the … Read more

© 2026 Archyworldys. All rights reserved.

For contact, advertising, copyright, issues email: [email protected]